Efficacy and Safety of Sugammadex in High-Risk Ambulatory Surgeries (Sugammadex)
Ambulatory Difficulty
About this trial
This is an interventional other trial for Ambulatory Difficulty focused on measuring high risk, chronic health condition, laparoscopic surgery
Eligibility Criteria
Inclusion Criteria:
- ASA physical score II and III
- Scheduled for a laparoscopic ambulatory surgery
- 21-60 years of age
- Able to understand and sign informed consent
Exclusion Criteria:
- Known allergy to neostigmine or sugammadex
- Active pulmonary diagnosis
- American Society of Anesthesia physical score 4 and above
- Known or suspected neuromuscular disease
- Documented renal or liver insufficiency (2 fold increase in the labs)
- Body Mass Index >40
- Any surgical case brought into the operating room after 4 PM (to avoid any provider bias related to discharging patients before closure of the ambulatory surgery center for the day)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
neostigmine
sugammadex
Neostigmine is the acetylcholinesterase inhibitor most commonly used in pharmacologically reversing the effects of neuromuscular blockers [8]. Reversal of NMB is facilitated by increasing acetylcholine levels at nicotinic skeletal muscle-binding sites.
Sugammadex is a modified gamma-cyclodextrin, the first of a new class of drugs called selective relaxant binding agents, with an unusually high affinity for rocuronium. This medication offers an alternate mechanism of action to antagonize the effects of steroidal neuromuscular blockade agents.